This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Corvaisier, S. Articles by Peyron, F. Search for Related Content PubMed PubMed Citation Articles by Corvaisier, S. Articles by Peyron, F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2004, p. 3794-3800, Vol. 48, No. 10
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.10.3794-3800.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Population Pharmacokinetics of Pyrimethamine and Sulfadoxine in Children Treated for Congenital Toxoplasmosis

Stéphane Corvaisier,¹ Bruno Charpiat,^1* Cyril Mounier,² Martine Wallon,³ Gilles Leboucher,¹ Mounzer Al Kurdi,³ Jean-François Chaulet,² and François Peyron³

Department of Pharmacy,¹ Department of Parasitology, Croix-Rousse Hospital,³ Desgenettes Army Teaching Hospital, Lyon, France²

Received 7 October 2003/ Returned for modification 14 January 2004/ Accepted 27 May 2004

The population pharmacokinetics of pyrimethamine (PYR) and sulfadoxine (SDX) for a group of 32 children with congenital toxoplasmosis was investigated by nonparametric modeling analysis. A one-compartment model was used as the structural model, and individual pharmacokinetic parameters were estimated by Bayesian modeling. PYR (1.25 mg/kg of body weight) and SDX (25 mg/kg) were administered orally every 10 days for 1 year, with adjustment of the dose to body weight every 3 months. Drug concentrations were measured by high-performance liquid chromatography. A total of 101 measurements in serum were available for both drugs. Mean absorption rate constants, volumes of distribution, elimination rate constants, and half-lives were 0.915 h^–1, 4.379 liters/kg, 0.00839 h^–1, and 5.5 days for PYR and 1.659 h^–1, 0.392 liters/kg, 0.00526 h^–1, and 6.6 days for SDX, respectively. Wide interindividual variability was observed. The estimated minimum and maximum concentrations of PYR in serum differed 8- and 25-fold among patients, respectively, and those of SDX differed 4- and 5-fold, respectively. Increases in the concentration of PYR were observed for eight children, and increases in the SDX concentration were observed for seven children. Serum PYR-SDX concentrations are unpredictable even when the dose is standardized for body weight. The concentrations of the PYR-SDX combination that are most efficacious for children have not yet been established. A model such as ours, associated with long-term follow-up, is needed to study the correlation between exposure to these two drugs and clinical outcome in children.

---

* Corresponding author. Mailing address: Department of Pharmacy, Croix-Rousse Hospital, 103 Grande Rue de la Croix-Rousse, 69317 Lyon Cedex 04, France. Phone: (33) 4-72-07-18-88. Fax: (33) 4-72-07-18-94. E-mail: bruno.charpiat{at}chu-lyon.fr.

---

Antimicrobial Agents and Chemotherapy, October 2004, p. 3794-3800, Vol. 48, No. 10
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.10.3794-3800.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Karunajeewa, H. A., Salman, S., Mueller, I., Baiwog, F., Gomorrai, S., Law, I., Page-Sharp, M., Rogerson, S., Siba, P., Ilett, K. F., Davis, T. M. E. (2009). Pharmacokinetic Properties of Sulfadoxine-Pyrimethamine in Pregnant Women. Antimicrob. Agents Chemother. 53: 4368-4376 [Abstract] [Full Text]  
• Meneceur, P., Bouldouyre, M.-A., Aubert, D., Villena, I., Menotti, J., Sauvage, V., Garin, J.-F., Derouin, F. (2008). In Vitro Susceptibility of Various Genotypic Strains of Toxoplasma gondii to Pyrimethamine, Sulfadiazine, and Atovaquone. Antimicrob. Agents Chemother. 52: 1269-1277 [Abstract] [Full Text]